Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Non-Current Assets (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Other Non-Current Assets for 17 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 23.99% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, down 23.99% year-over-year, with the annual reading at $4.5 million for FY2025, 23.99% down from the prior year.
  • Other Non-Current Assets hit $4.5 million in Q4 2025 for Ironwood Pharmaceuticals, down from $4.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $6.3 million in Q3 2024 to a low of $485000.0 in Q1 2021.
  • Historically, Other Non-Current Assets has averaged $2.7 million across 5 years, with a median of $2.2 million in 2022.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 50.05% in 2021 and later soared 734.71% in 2024.
  • Year by year, Other Non-Current Assets stood at $485000.0 in 2021, then grew by 3.09% to $500000.0 in 2022, then soared by 621.6% to $3.6 million in 2023, then skyrocketed by 64.16% to $5.9 million in 2024, then fell by 23.99% to $4.5 million in 2025.
  • Business Quant data shows Other Non-Current Assets for IRWD at $4.5 million in Q4 2025, $4.8 million in Q3 2025, and $5.2 million in Q2 2025.